Given that this was a retrospective study and given the heterogeneity of treatment and tumor staging across different lines of treatment, we did not analyze the impact of SMAD4 and TP53 co-mutation on progression-free survival or response rate. This evidence concerns the gene SMAD4 and neoplasm.